Galmed signed term sheet for the development of novel semaglutide sublingual formulation

The proprietary self-emulsifying drug delivery system (sedds) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as glp-1 (semaglutide, liraglutide etc.). the new formulation is expected to offer alternatives to both approved injectable semaglutide (ozempic© and wegovy©) and oral form (rybelsus©), providing a non-invasive route that allows the medication to enter the bloodstream through the oral mucous membranes.
GLMD Ratings Summary
GLMD Quant Ranking